Active case
Drugs designed to prevent blindness shouldn’t make your vision worse. Some patients, however, are reporting suffering from retinal vasculitis and/or retinal vascular occlusion of varying degrees after receiving Syfovre injections. Such inflation can worsen eyesight and even lead to blindness. If you, or someone you know, experienced IOI related to Syfovre injections, you may have a claim.
Syfovre Background
Syfovre (pegcetacoplan injection) is manufactured by Apellis Pharmaceuticals, Inc. The drug received FDA approval on February 17, 2023, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (ARMD or AMD).
This is the first treatment for geographic atrophy, which is a progressive and irreversible disease which can occur in patients with an advanced form of AMD. GA is a leading cause of blindness in patients with AMD as it affects the central vision. Syfovre is a targeted C3 therapy intended to regulate excessive activation of the complement cascade — part of the body’s immune system.
Vison loss reported after using Syfovre
In July 2023, the American Society of Retinal Specialists (ASRS) Research and Safety in Therapeutics Committee issued a member communication showing multiple reports of retinal vasculitis and retinal vascular occlusion in patients who received the Syfovre injection. As of December 1, 2023, Apellis Pharmaceuticals, Inc. confirmed there were 12 events of retinal vasculitis and two additional suspected cases.
Some patients receiving Syfovre injections suffered from intra-ocular inflammation (IOI) of varying degrees, retinal vasculitis and occlusive retinal vasculitis after a single injection of Syfovre.
Has Syfovre been recalled?
Syfovre has not been recalled by the U.S. FDA or Apellis Pharmaceuticals, Inc. In November 2023, the manufacturer updated safety information for Syfovre, specifically an update to the Warnings and Precautions and the Adverse Reactions sections of the U.S. Prescribing Information. The label change added a warning for retinal vasculitis and/or retinal vascular occlusion.
Contact Us
If you, or your loved one, received a Syfovre injection and now suffers from worsening vision, specifically retinal vasculitis, retinal vascular occlusion, intraocular inflammation or blindness, you may be eligible to pursue compensation. Complete this webform or call 1.800.768.4026 to contact attorney Kimberly D. Barone Baden or Ann E. Rice Ervin.
Our medical drug litigation experience
Motley Rice medical attorneys have represented thousands of patients seriously hurt by dangerous prescription and over-the-counter drugs.
As a patient or family member, what you know about your or a loved one’s medications may be limited. We understand that. If you believe a medicine made you sick or hurt you, our attorneys have the resources needed to thoroughly investigate and:
- Identify potentially harmful medicines
- Review if the medicine hurt you
- Review the medicine manufacturer’s compliance with FDA regulations
- Examine the adequacy of the manufacturer's warning to you about potential side effects
- Recognize other issues that could affect your potential claim
Learn more about our medical drug experience here
Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death. Syfovre remains approved by the U.S. Food and Drug Administration.
Working with Us
Wondering what happens when you submit a form or give us a call? We spend time gathering information from you, and your initial call is always free.
What's important?
- Names
- Dates
- Timeline of events
- Related documents